Akin Atmaca
Impact in
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
-
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 27
- Cancer Immunotherapy and Biomarkers 15
- Lung Cancer Research Studies 10
- CAR-T cell therapy research 5
-
- Lung Cancer Treatments and Mutations 12
- Gastric Cancer Management and Outcomes 9
- Lung Cancer Diagnosis and Treatment 3
- Co-authors
- Elke Jäger (32 shared papers)Alexander K. Knuth (12 shared papers)Claudia Pauligk (11 shared papers)Matthew David Hellmann (4 shared papers)Scott Joseph Antonia (4 shared papers)Salah‐Eddin Al‐Batran (15 shared papers)Paolo A. Ascierto (3 shared papers)Margaret K. Callahan (3 shared papers)
- Journals
- Annals of Oncology (7 papers)BMC Cancer (3 papers)British Journal of Cancer (3 papers)International Journal of Cancer (3 papers)Journal of Clinical Oncology (3 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Akin Atmaca
51 papers receiving 4.8k citations
Akin Atmaca's Hit Papers
Peers
Comparison fields: 5 of 79
- Oncology 2.6k
- Pulmonary and Respiratory Medicine 1.3k
- Immunology 325
- Cancer Research 198
- Surgery 292
Countries citing papers authored by Akin Atmaca
This map shows the geographic impact of Akin Atmaca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akin Atmaca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akin Atmaca more than expected).
Fields of papers citing papers by Akin Atmaca
This network shows the impact of papers produced by Akin Atmaca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akin Atmaca. The network helps show where Akin Atmaca may publish in the future.
Co-authors
The 25 scholars most cited alongside Akin Atmaca, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial Hit paper breakdown → | 2016 | 1068 |
| 2 | Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 776 |
| 3 | Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie Hit paper breakdown → | 2008 | 629 |
| 4 | 2018 | 260 | |
| 5 | 2019 | 251 | |
| 6 | 2008 | 215 | |
| 7 | 2007 | 167 | |
| 8 | 2004 | 163 | |
| 9 | 2019 | 136 | |
| 10 | Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study Hit paper breakdown → | 2024 | 136 |
| 11 | 2011 | 86 | |
| 12 | 2005 | 83 | |
| 13 | 2011 | 75 | |
| 14 | 2010 | 69 | |
| 15 | 2006 | 62 | |
| 16 | 2016 | 59 | |
| 17 | 2005 | 57 | |
| 18 | LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. | 2007 | 50 |
| 19 | 2013 | 49 | |
| 20 | 2019 | 46 |
About Akin Atmaca
Akin Atmaca is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Cancer Research and Molecular Biology, having authored 55 papers that have together received 4.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (12 papers), Immunotherapy and Immune Responses (10 papers), Lung Cancer Research Studies (10 papers), Gastric Cancer Management and Outcomes (9 papers), CAR-T cell therapy research (5 papers), Histone Deacetylase Inhibitors Research (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). The work is most often cited by research in Oncology (2.6k citations), Pulmonary and Respiratory Medicine (1.3k citations), Immunology (325 citations), Cancer Research (198 citations) and Surgery (292 citations). Akin Atmaca has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Elke Jäger, Alexander K. Knuth, Claudia Pauligk, Matthew David Hellmann, Scott Joseph Antonia, Salah‐Eddin Al‐Batran, Paolo A. Ascierto, Margaret K. Callahan, Emiliano Calvo and Gernot Seipelt. Their work appears in journals such as Annals of Oncology, BMC Cancer, British Journal of Cancer, International Journal of Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.